Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Miwako Kobayashi, Jennifer L. Farrar, Ryan Gierke, Amadea Britton, Lana Childs, Andrew J. Leidner, Doug Campos‐Outcalt, Rebecca L. Morgan, Sarah S. Long, H. Keipp Talbot, Katherine A. Poehling, Tamara Pilishvili
Abstract
approach to guide its deliberations regarding use of these vaccines. Before this, PCV13 and PPSV23 were recommended for use for U.S. adults and the recommendations varied by age and risk groups. This was simplified in the new recommendations.
Topics & Concepts
Pneumococcal conjugate vaccineMedicinePneumococcal polysaccharide vaccineAdvisory committeeVaccinationImmunizationFood and drug administrationConjugate vaccineSerotypeFamily medicinePneumococcal diseasePediatricsAntibodyImmunologyStreptococcus pneumoniaeEnvironmental healthManagementEconomicsGeneticsBacteriaBiologyPneumonia and Respiratory InfectionsRespiratory viral infections researchInfluenza Virus Research Studies